CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Up 15.0% in January

CytoDyn Inc. (OTCMKTS:CYDY) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 20,123,400 shares, an increase of 15.0% from the December 31st total of 17,499,100 shares. Based on an average daily volume of 6,176,200 shares, the short-interest ratio is presently 3.3 days.

CytoDyn Trading Up 4.3 %

OTCMKTS:CYDY opened at $0.20 on Friday. The company has a market cap of $243.09 million, a PE ratio of -19.80 and a beta of -0.10. The company has a 50 day simple moving average of $0.14 and a two-hundred day simple moving average of $0.14. CytoDyn has a 12 month low of $0.10 and a 12 month high of $0.32.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.